KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Co-Diagnostics (CODX) Short-term Investments (2018 - 2025)

Historic Short-term Investments for Co-Diagnostics (CODX) over the last 8 years, with Q2 2025 value amounting to $2.2 million.

  • Co-Diagnostics' Short-term Investments fell 9275.44% to $2.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $2.2 million, marking a year-over-year decrease of 9275.44%. This contributed to the annual value of $26.8 million for FY2024, which is 3855.11% down from last year.
  • According to the latest figures from Q2 2025, Co-Diagnostics' Short-term Investments is $2.2 million, which was down 9275.44% from $19.6 million recorded in Q1 2025.
  • In the past 5 years, Co-Diagnostics' Short-term Investments ranged from a high of $68.9 million in Q1 2023 and a low of $983614.0 during Q1 2022
  • Moreover, its 5-year median value for Short-term Investments was $23.2 million (2024), whereas its average is $24.2 million.
  • Per our database at Business Quant, Co-Diagnostics' Short-term Investments surged by 690686.8% in 2023 and then plummeted by 9275.44% in 2025.
  • Over the past 5 years, Co-Diagnostics' Short-term Investments (Quarter) stood at $1.3 million in 2021, then soared by 4543.56% to $58.3 million in 2022, then dropped by 25.15% to $43.6 million in 2023, then crashed by 38.55% to $26.8 million in 2024, then tumbled by 91.62% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q2 2025, $19.6 million for Q1 2025, and $26.8 million during Q4 2024.